ARHGEF3

Across TCGA pan-cancer cohorts, ARHGEF3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARHGEF3 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARHGEF3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGEF3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and OV show a favorable association.

HNSC, OV, and LUAD are the cancer types where ARHGEF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.866	0.578	.023	7	view →
OV	DFS	Median	All	1.000	0.622	.025	4	view →
LUAD	OS	Tertile	All	0.596	1.000	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARHGEF3–HNSC (DFS)

Open the HNSC breakdown →